Back to Search Start Over

Lipidomics reveals the dynamics of lipid profile altered by omega‐3 polyunsaturated fatty acid supplementation in healthy people

Authors :
Hongfeng Jiang
Ding Ai
Qian Cheng
Meng Yan
Tong Hua
Xu Zhang
Wenbin Cai
Source :
Clinical and Experimental Pharmacology and Physiology. 47:1134-1144
Publication Year :
2020
Publisher :
Wiley, 2020.

Abstract

Glycerophospholipids (GPs) and sphingolipids (SPs) are important lipid components in the body and play biological functions. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) are important nutrients, and their supplements are commonly used for preventing some diseases. However, the effect of n-3 PUFAs on the human glycerophospholipidome and sphingolipidome is unclear. We used targeted lipidomics to study the GP and SP profile of healthy individuals after supplementation with n-3 PUFAs for 3, 7, 14 and 21 days. Fuzzy c-means clustering was used to cluster the lipid species into six classes reflecting different changed-content patterns after n-3 PUFA supplementation. Among the species with significantly changed content, lysophospholipids were the most sensitive; their content started to increase on day 3. The content of phosphatidylserines increased at a later stage. The content of most of the phosphatidylcholines and alkylphosphatidylcholines decreased on day 21. A correlation network analysis of lipid species suggested that some enzymes involved in the metabolism of lysophospholipids and phosphatidylserines were regulated by n-3 PUFAs. Levels of creatine kinase-MB (CK-MB), urea, glucose, triglycerides and total bilirubin were altered by n-3 PUFA at 21 days. Correlation analysis revealed that the level of CK-MB was negatively correlated with those of species in lysophosphatidic acid, lysophosphatidylcholine, lysophosphatidylethanolamine and phosphatidylserine classes, which were increased by n-3 PUFA supplementation. With the analysis in this work, we demonstrated the regular pattern of n-3 PUFAs on GP and SP metabolism, which provides a pharmacological basis for n-3 PUFAs for clinical application.

Details

ISSN :
14401681 and 03051870
Volume :
47
Database :
OpenAIRE
Journal :
Clinical and Experimental Pharmacology and Physiology
Accession number :
edsair.doi.dedup.....05d7aa64b9860d8448f0872718778263